237 results
Page 2 of 12
6-K
EX-99
u7ltcs89kbmgc
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
9qdgn44glk9x1
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
r9eaicgvremaa4x
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
rjy6mqtyf 8okoi
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
a6t940c
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
ubh35qpi3 r2
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
lubns f5wsh14bzr
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
ac635m vpnwhb
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
psz1sv95kihi1
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
ei3m2yqh
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
o0698309p4p 5ivj
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
pxxm3sg5sa5khs3j
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
yibq 2a8qx6
25 Apr 23
Current report (foreign)
7:07am
6-K
EX-99
7sjee3 2ind1w7355e8
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
6o69e1a
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
6-K
EX-99
kfaku qpjh
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
l4n9sa
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
0qnm6p8 n61b1foti8o
10 Nov 22
Current report (foreign)
7:08am
6-K
EX-99
iuu3 nt0sk
4 Nov 22
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4:35pm
6-K
EX-99
23gyh5a6exfae34by
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am